Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526079 · ClinicalTrials.gov registry record · Phase 2
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
A Phase 2 study of Rectal Cancer, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05526079 is a Phase 2 study of Rectal Cancer that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 30 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05526079, a Phase 2 study of Rectal Cancer, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to those patients whose tumors demonstrate "regrowth" will maintain acceptable local control and overall survival rate for the whole cohort.
Conditions Studied
Interventions
- OTHER Watchfuf waiting
Study Locations (1)
Michigan
- Ascension St. John Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2029-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05526079
The ClinicalTrials.gov registry entry for NCT05526079 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Watchfuf waiting is the first listed.
NCT05526079 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05526079 about?
NCT05526079 is a clinical study titled "Watchful Waiting for Complete Responders to Therapy in Rectal Cancer". The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial "non-operative management" approach, with an offer of radical resection only to...
What is the current status of trial NCT05526079?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-07-10. Estimated completion is 2029-07-09.
What conditions does trial NCT05526079 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT05526079?
The interventions under investigation include: Watchfuf waiting (OTHER).
Who is sponsoring clinical trial NCT05526079?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05526079 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.